DECITABINE

SynDRA canonical compound SYN0023417 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	DNMT1
Mechanism of action	DNA methyltransferase inhibitor
Indication	anemia \| chronic myeloid leukemia (CML) \| myelodysplastic diseases (MDS)
Disease area	hematologic malignancy \| hematology

All known targets

decitabine mesylate
decitabine mesilate
dacogen
Decitabina
2'-deoxy-5-azacytidine
DAC
NSC-127716
Dacogen
Decitabine component of astx-727
Decitabine component of astx727
Decitabine component of inqovi
AzadC
Dezocitidine
NCGC_5ADOC
Dacogen (TN)
E-7373
Decitabine (USAN/INN)
Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine
2'-Deoxy-5-azacytidine
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
5-AZAdC
5-Aza-2′-Deoxycytidine
5-Aza-2'-deoxycytidine
5-Azadeoxycytidine
5-Deoxy-2′-azacytidine
5-aza-2-deoxycytidine
5-aza-CdR
5-aza-dC
5A2dc
Dac
5-Aza-deoxycytidine
Alpha-Decitibine
4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
C8H12N4O4
MLS001332587